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Abstract BRCA1-mutated breast cancer is associated
with basal-like disease; however, it is currently unclear if
the presence of a BRCA1 mutation depicts a different entity
within this subgroup. In this study, we compared the
molecular features among basal-like tumors with and
without BRCA1 mutations. Fourteen patients with BRCA1-
mutated (nine germline and five somatic) tumors and basal-
like disease, and 79 patients with BRCA1 non-mutated
tumors and basal-like disease, were identified from the
cancer genome atlas dataset. The following molecular data
types were evaluated: global gene expression, selected
protein and phospho-protein expression, global miRNA
expression, global DNA methylation, total number of
somatic mutations, TP53 and PIK3CA somatic mutations,
and global DNA copy-number aberrations. For intrinsic
subtype identification, we used the PAM50 subtype pre-
dictor. Within the basal-like disease, we observed minor
molecular differences in terms of gene, protein, and
miRNA expression, and DNA methylation variation,
according to BRCA1 status (either germinal or somatic).
However, there were significant differences according to
average number of mutations and DNA copy-number
aberrations, and four amplified regions (2q32.2, 3q29,
6p22.3, and 22q12.2), which are characteristic in high-
grade serous ovarian carcinomas, were observed in both
germline and somatic BRCA1-mutated breast tumors.
These results suggest that minor, but potentially relevant,
baseline molecular features exist among basal-like tumors
according to BRCA1 status. Additional studies are needed
to better clarify if BRCA1 genetic status is an independent
prognostic feature, and more importantly, if BRCA1
mutation status is a predictive biomarker of benefit from
DNA-damaging agents among basal-like disease.




BRCA1 Breast cancer 1 early onset
Aleix Prat and Cristina Cruz have contributed equally to this work.
Electronic supplementary material The online version of this
article (doi:10.1007/s10549-014-3056-x) contains supplementary
material, which is available to authorized users.
A. Prat (&)
Translational Genomics Group, Vall d´Hebron Institute of
Oncology (VHIO), Pg Vall d´Hebron, 119-129, 08035 Barcelona,
Spain
e-mail: aprat@vhio.net
C. Cruz  J. Balman˜a
High Risk and Cancer Prevention Group, Vall d´Hebron Institute




K. A. Hoadley  C. M. Perou
Lineberger Comprehensive Cancer Center, University of North





Oncogenetics Group, Hospital Universitari de la Vall d´Hebron,




Breast Cancer Res Treat (2014) 147:185–191
DOI 10.1007/s10549-014-3056-x
ID4 Inhibitor of DNA binding 4, dominant negative
helix-loop-helix protein
PIK3CA Phosphatidylinositol-4, 5-bisphosphate
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Introduction
Studies based on gene expression data have identified and
characterized four main intrinsic subtypes of breast cancer
(luminal A, luminal B, HER2-enriched, and basal-like) [1,
2]. Among them, the basal-like subtype is associated with
young age, BRCA1 germline and somatic mutations [1, 3,
4] and an overall poor prognosis despite that a subgroup of
patients with these tumors has an excellent outcome when
treated with chemotherapy [5]. In the clinical setting, basal-
like tumors are usually identified by the lack of expression
of hormone receptors by immunohistochemistry (IHC) and
lack of overexpression of HER2 by IHC and/or FISH (the
so called triple-negative [TN] status) [1, 2, 6]. Although the
TN definition enriches for basal-like disease, considerable
discordance exists [2, 6].
BRCA1 mutations and other associated molecular traits
might confer sensitivity to specific therapeutic agents [7–
10]. Nevertheless, it is unclear how different, from a bio-
logical perspective, BRCA1-mutated basal-like tumors are
from BRCA1 non-mutated basal-like tumors, and whether
BRCA1 mutation is an independent prognostic and/or pre-
dictive biomarker when the intrinsic subtype is taken into
account [11–15]. This line of thought directed us to for-
mulate the question of how much the biology of basal-like
tumors with BRCA1 mutations differs from the biology of
basal-like tumors without BRCA1 mutations. To address
this question, we interrogated The Cancer Genome Atlas
(TCGA) breast cancer project which provides various types
of molecular data coming from DNA, RNAs, and proteins
[1].
Methods
The Cancer Genome Atlas dataset
In this study, we evaluated TCGA breast cancer dataset and all
data were obtained from the TCGA breast cancer online portal
(https://tcga-data.nci.nih.gov/docs/publications/brca_2012/).
The following files were used. For microarray gene expres-
sion data: ‘‘BRCA.exp.547.med.txt.’’ For reverse-phase
protein array (RPPA) expression data: ‘‘rppaData-
403Samp-171Ab-Trimmed.txt.’’ For sequencing miRNA
expression: ‘‘BRCA.780.mimat.txt.’’ For microarray DNA
methylation variation: ‘‘BRCA.methylation.27 k.450 k.txt.’’
For microarray DNA copy-number aberration data:
‘‘brca_scna_all_thresholded.by_genes.txt.’’ For intrinsic
subtype identification, we used the PAM50 subtype calls as
provided in the TCGA portal.
Independent dataset
We evaluated an independent and publicly available
microarray-based gene expression dataset (GSE40115) that
includes breast tumors from 32 patients with basal-like
disease (20 with BRCA1 germline mutations and 12 with
sporadic tumors [i.e. unknown BRCA1 status]). The file
‘‘GSE40115-GPL15931_series_matrix.txt’’ with the nor-
malized log2 ratios (Cy5 sample/Cy3 control) of probes
was used. Probes mapping to the same gene (Entrez ID as
defined by the manufacturer) were averaged to generate
independent expression estimates.
Seven-TN subtype classification
To identify the 7-TN subtypes described by Lehmann et al.
[16], (i.e., basal one, basal two, immunomodulatory,
luminal androgen receptor, mesenchymal, mesenchymal
stem cell, and unstable), we submitted the raw gene
expression data of each individual dataset of basal-like
disease to the TNBC type online predictor (http://cbc.mc.
vanderbilt.edu/tnbc/) [17].
Statistical analysis
All multiple-testing comparisons were done using an unpaired
two-class significance analysis of microarrays (SAM, http://
www-stat.stanford.edu/*tibs/SAM/). The mutation rates of
TP53 and PIK3CA genes between two groups, the 7-TN
subtype distribution between BRCA1-mutated and non-
mutated basal-like tumors, and the amplification rates of ID4
between two groups, were compared using the Chi square and
Fisher’s exact tests. The total number of somatic mutations
between two groups was compared using a Student’s t test. All
statistical computations were performed in R v.2.15.1 (http://
cran.r-project.org).
Results and discussion
From TCGA breast cancer dataset, we identified 12 tumor
samples with BRCA1 germline mutations (all classified as
deleterious), seven tumor samples with somatic BRCA1
mutations, and one tumor sample with both BRCA1
germline and somatic mutations (Supplemental Material).
As expected, 70 % of BRCA1 mutated tumors where of the
basal-like intrinsic subtype (nine germline and five
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somatic), but luminal A (two germline, one germline/
somatic, and one somatic), luminal B (one germline), and
HER2-enriched (one somatic) tumors were also identified
(Fig. 1). Similarly, 66.7 % of BRCA1 mutated tumors were
TN.
Within basal-like disease, we observed minor molecular
differences (0–1.1 %) in terms of gene expression, protein
expression, miRNA expression, and DNA methylation
variation according to BRCA1 status (Table 1 and Sup-
plemental Material). Indeed, no genes among 17,876 genes
were found differentially expressed between basal-like
BRCA1-mutated tumors versus basal-like BRCA1 non-
mutated tumors (Table 1), including the BRCA1 mRNA
transcript (Fig. 2). Similar results were observed when only
the tumors with BRCA1 germline mutations were taken
into consideration (Supplemental Material). Concordant
with this result, analysis of microarray gene expression
data of an independent dataset of 32 tumors with basal-like
disease (20 with a BRCA1 germline mutation and 12 with
sporadic tumors) revealed only 0.03 % differentially
expressed genes (6 of 21,848, false discovery rate
Fig. 1 Intrinsic profile of BRCA1-mutated breast tumors. Hierarchical clustering of 509 breast samples of the cancer genome atlas (TCGA)
project using the *1,900 intrinsic gene list [30]. PAM50 intrinsic subtype calls [30] and BRCA1 mutation status is shown below the array tree
Table 1 Significant molecular
differences between basal-like
BRCA1-mutated tumors
(n = 14) and basal-like BRCA1
non-mutated tumors (n = 79)
RPPA reverse-phase protein
arrays, FDR false discovery rate
BRCA1WT BRCA1 wild-type,
BRCA1MUT BRCA1 mutated












17,786 (unique genes) Expression BRCA1MUT 0 0
BRCA1WT 0
171 (unique proteins or
phospho-proteins by
RPPA)




Expression BRCA1MUT 3 0.2
BRCA1WT 0
530 (unique genes) Methylation BRCA1MUT 0 1.1
BRCA1WT 6




Fig. 2 Relative BRCA1 gene expression in basal-like disease based
on BRCA1 mutational status. Data have been obtained from the
TCGA breast cancer project. The BRCA1 gene expression has been
median centered across all breast cancer samples with DNA-seq data
(i.e., basal-like and not basal-like). The p-value was calculated by
comparing gene expression means across the three groups. In red
color, breast samples with C2-fold decrease in BRCA1 expression
compared to its median expression in breast cancer are shown
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[FDR] = 0 %) between the two groups [18] (Supplemental
Material). In addition, we did not identify significant dif-
ferences in the proportion of the recently reported 7-TN
subtype classification proposed by Lehmann and col-
leagues [16], between basal-like tumors with and without
BRCA1 mutations (Supplemental Material). Interestingly,
two clear groups within the basal-like BRCA1 wild-type
disease were identified based on BRCA1 mRNA expres-
sion-only (i.e., high and low) (Fig. 2).
In terms of DNA copy-number aberrations, we identified
250 genes (representing 14 different DNA regions and
1.3 % of all genes evaluated) showing higher amplification
rates in basal-like BRCA1-mutated tumors compared to
basal-like BRCA1 wild-type tumors (Table 2). Among
Table 2 DNA regions found significantly more amplified in basal-like BRCA1-mutated tumors (n = 14) compared to basal-like BRCA1 non-




6p22.3 6p22.3 FAM65B, TDP2, ACOT13, ALDH5A1, GPLD1, KIAA0319, MRS2, C6orf62, GMNN, DCDC2, CMAHP,
KAAG1, KIF13A, DEK, NRSN1, E2F3, MBOAT1, RNF144B, CDKAL1, KDM1B, NHLRC1, TPMT, ID4,
HDGFL1, PRL, LINC00340, SOX4, CAP2, FAM8A1, NUP153, RBM24, MYLIP, GMPR, ATXN1,
DTNBP1, JARID2
3q29 3q29 FYTTD1, KIAA0226, DLG1, BDH1, LOC220729, CEP19, LOC152217, MFI2, NCBP2, PAK2, PIGX, PIGZ,
SENP5, ACAP2, ANKRD18DP, FAM157A, LMLN, IQCG, LRCH3, C3orf43, FBXO45, LRRC33,
RNF168, UBXN7, WDR53, APOD, MUC20, MUC4, OSTalpha, PCYT1A, PPP1R2, SDHAP1, SDHAP2,
TCTEX1D2, TFRC, TM4SF19, TNK2, ZDHHC19, XXYLT1, FAM43A, LSG1, TMEM44, RPL35A,
ATP13A3, ATP13A4, ATP13A5, CPN2, GP5, HES1, HRASLS, LOC100128023, LOC100131551,
LRRC15, MB21D2, MGC2889, OPA1
2q32.2 2q32.2 COL3A1, COL5A2, DIRC1, NAB1, TMEM194B, C2orf88, GLS, HIBCH, INPP1, MFSD6, MSTN, STAT4,
SLC40A1, WDR75, ORMDL1, OSGEPL1, PMS1, ANKAR, ASNSD1, STAT1
22q12.2 22q12.2 AP1B1, ASCC2, CABP7, CCDC157, DEPDC5, DRG1, DUSP18, EIF4ENIF1, EMID1, EWSR1, GAL3ST1,
GAS2L1, GATSL3, HORMAD2, INPP5 J, LIF, LIMK2, MORC2, MORC2-AS1, MTFP1, MTMR3, NEFH,
NF2, NIPSNAP1, OSBP2, OSM, PATZ1, PES1, PIK3IP1, PISD, PLA2G3, PRR14L, RASL10A, RFPL1,
RFPL1-AS1, RHBDD3, RNF185, RNF215, SDC4P, SEC14L2, SEC14L3, SEC14L4, SELM, SF3A1, SFI1,
SLC35E4, SMTN, SNORD125, TBC1D10A, TCN2, THOC5, TUG1, UQCR10, ZMAT5
10q25.3 – TRUB1, CASP7, ATRNL1,FAM160B1, PDZD8, SLC18A2, C10orf96, C10orf81, DCLRE1A, HABP2,
NHLRC2, NRAP, KCNK18, KIAA1598, VAX1, GFRA1, PNLIP, PNLIPRP1, PNLIPRP2, PNLIPRP3,
C10orf82, HSPA12A, ADRB1, AFAP1L2, C10orf118, TDRD1, VWA2, ABLIM1
10q26.11 – PRLHR, FAM204A, BAG3, INPP5F, TIAL1, C10orf46, MCMBP, SEC23IP, CASC2, EMX2, EMX2OS,
RAB11FIP2, EIF3A, FAM45A, GRK5, NANOS1, PRDX3, RGS10, SFXN4, SNORA19
22q11.22 – GGTLC2, GNAZ, LOC648691, LOC96610, POM121L1P, PPM1F, PRAME, RAB36, RTDR1, TOP3B,
VPREB1, ZNF280A, ZNF280B
22q11.23 – ADORA2A, BCR, BCRP3, C22orf13, C22orf15, C22orf43, C22orf45, CABIN1, CHCHD10, CRYBB2,
CRYBB3, DDT, DDTL, DERL3, FAM211B, GGT1, GGT5, GSTT1, GSTT2, GSTTP1, GSTTP2,
GUSBP11, IGLL1, IGLL3P, KIAA1671, LOC391322, LRP5L, MIF, MMP11, PIWIL3, POM121L10P,
POM121L9P, RGL4, SGSM1, SLC2A11, SMARCB1, SNRPD3, SPECC1L, SUSD2, TMEM211, TOP1P2,
UPB1, VPREB3, ZDHHC8P1, ZNF70
22q12.1 – ADRBK2, ASPHD2, C22orf31, CCDC117, CHEK2, CRYBA4, CRYBB1, HPS4, HSCB, KREMEN1, MIAT,
MN1, MYO18B, PITPNB, SEZ6L, SRRD, TFIP11, TPST2, TTC28, TTC28-AS1, XBP1, ZNRF3
22q12.3 – C22orf24, C22orf42, SLC5A1, YWHAH, BPIFC, C22orf28, FBXO7, RFPL2, RFPL3, RFPL3-AS1, SLC5A4,
SYN3, APOL5, APOL6, HMOX1, MB, MCM5, RASD2,TOM1, TIMP3, CACNG2, IFT27, PVALB, NCF4,
C1QTNF6, C22orf33, CSF2RB, IL2RB, KCTD17, MPST, TMPRSS6, TST, ISX, HMGXB4, LARGE,
APOL3, RBFOX2, EIF3D, FOXRED2, TXN2, APOL1, MYH9, APOL2, APOL4
2q32.1 – ZSWIM2, ZNF804A, FAM171B, ITGAV, GULP1, CALCRL, TFPI, ZC3H15, DNAJC10, DUSP19, NUP35,
FRZB, NCKAP1, PDE1A
2q33.2 – CTLA4, ICOS, CD28, RAPH1, FAM117B, ICA1L, ABI2, ALS2CR8, WDR12, CYP20A1, NBEAL1
3q28 – CCDC50, FGF12, OSTN, PYDC2, UTS2D, CLDN1, CLDN16, GMNC, IL1RAP, LEPREL1, SNAR-I,
TMEM207, TP63, TPRG1
6p21.31 – NUDT3, C6orf1, HMGA1, BAK1, GGNBP1, LINC00336, ANKS1A, C6orf126, C6orf127, C6orf81, CLPS,
FKBP5, GRM4, LHFPL5, LOC285847, SCUBE3, SNRPC, SRPK1, TAF11, TCP11, UHRF1BP1,
SLC26A8, C6orf125, IP6K3, ITPR3, LEMD2, MLN, RPL10A, TEAD3, TULP1, ZNF76, C6orf106,
PACSIN1, RPS10, SPDEF, BRPF3, C6orf222, MAPK13, MAPK14, PNPLA1, DEF6, FANCE, PPARD,
ETV7, PXT1, KCTD20, SRSF3, STK38
HGSOC high-grade serous ovarian carcinoma
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them, we identified four regions (2q32.2, 3q29, 6p22.3, and
22q11.2) that have been previously shown to be amplified
and characteristic of high-grade serous ovarian carcinomas
[19]. Interestingly, region 6p22.3 contains ID4, a gene long
known to be a marker of basal-like breast cancers [20], and
known to code for a DNA-binding protein that negatively
regulates BRCA1 expression in breast and ovarian cancers
[21]. This gene was found amplified (i.e. low or high gains)
in 78.6 % (11/14) of basal-like BRCA1 mutated tumors
versus 35.1 % (26/74) of basal-like BRCA1 wild-type
tumors (p = 0.008, Fisher’s exact test). Similar results
were observed when the BRCA1 somatic mutations were
excluded (Supplemental Material). The biological role of
ID4 amplification in BRCA1 mutated breast cancer is cur-
rently unknown, and we could hypothesize that ID4 might
inhibit residual function of mutant BRCA1.
In terms of somatic gene mutations, basal-like BRCA1
mutated tumors showed higher average number of muta-
tions than basal-like BRCA1 wild-type tumors (122.6 vs.
80.3, p = 0.004, Student’s t test). Regarding the distri-
bution of TP53 and PIK3CA somatic mutations according
to BRCA1 status, TP53 mutations were found in 100 %
(14/14) of basal-like BRCA1 mutated versus 75.9 % (60/
79) of basal-like BRCA1 wild-type tumors (p = 0.065,
Fisher’s exact test). Finally, PIK3CA mutations were
found in 0 % (0/14) of basal-like BRCA1 mutated tumors
versus 10.1 % (8/79) of basal-like BRCA1 wild-type
tumors (p = 0.602).
In our analysis, most of the unique molecular features of
basal-like BRCA1 mutated tumors were found at the DNA
level (i.e. amplifications and mutation rates). Indeed, basal-
like BRCA1 mutated tumors showed higher amplification
rates at 14 different chromosomal regions and higher
number of somatic mutations, including TP53, compared to
basal-like BRCA1 wild-type tumors. However, no signifi-
cant differences in protein expression were found when
comparing basal-like BRCA1 mutated and BRCA1 wild-
type tumors. These results suggest that the genomic
instability induced by BRCA1 loss [22] does not translate
into a recognizable phenotype at the RNA and protein
level. The potential explanation of these findings is cur-
rently unknown. Nonetheless, the fact that 4 out of 14
(28.5 %) amplified DNA regions were found to be char-
acteristic regions of high-grade serous ovarian carcinomas
suggests that, among basal-like breast tumors, those with a
BRCA1 mutation are more similar to ovarian carcinoma at
the genetic level.
In our analysis, the absence of recognizable prominent
differences in molecular alterations based on BRCA1
mutation status would be in line with previous clinical data
suggesting that BRCA1 status per se might not play a major
role in conferring a distinct prognosis within basal-like
disease. Results from three retrospective studies that have
evaluated the prognostic role of BRCA1/2 mutations
(mostly BRCA1) in TN breast cancer support this hypoth-
esis [13–15]. In Bayraktar et al. [13], BRCA1/2 status was
not found to be prognostic in 227 women with early TN
breast cancer referred to genetic counseling. Similar results
were observed in a cohort of 195 patients with metastatic
breast cancer, where the independent prognostic value of
BRCA1 in univariate analyses was lost when TN status and
other clinical-pathological variables were taken into
account [14]. More recently, Huzarski et al. [15] evaluated
the association of germline BRCA1 mutation status with
10 year overall survival in 3,350 polish women with a
diagnosis of breast cancer. The authors observed that
BRCA1 mutation status was significantly associated with
worse outcome when standard clinical-pathological vari-
ables were taken into account [15]. However, among
patients with TN breast cancer, BRCA1 status was not
associated with worse outcome [15].
The role of the BRCA1 mutation status as a predictive
factor of treatment response among TN breast cancer is
also under study. On the one hand, two retrospective
studies have evaluated the ability of BRCA1 mutation
status to predict response to multi-agent chemotherapy [11,
12]. In the first study, Arun and colleagues showed no
significant differences in terms of pathological complete
response rates after neoadjuvant chemotherapy (mostly
anthracycline/taxane-based) among 75 patients with TN
breast cancer in relation to their BRCA1 status [11]. In the
second study, Gonzalez-Angulo et al. [12] observed a
better outcome in BRCA1/2 mutated TN breast cancer
compared to BRCA1/2 non-mutated TN breast cancers after
treatment with adjuvant anthracycline/taxane-based che-
motherapy. On the other hand, two recent prospective
clinical trials (GeparSixto [23] and CALGB40603 [24])
have demonstrated the value of adding carboplatin, a DNA-
damaging agent, to standard neoadjuvant anthracycline/
taxane-based chemotherapy in 769 patients with newly
diagnosed TN breast cancer, regardless of their BRCA1
mutational status.
Previous retrospective studies have suggested that
BRCA1 mutated tumors might substantially benefit from
platinum [9, 25]. In fact, in the GeparSixto TN trial [23,
26], recent data reported higher pCR rates in BRCA1/2-
mutated patients compared to BRCA1/2 non-mutated
patients. Nevertheless, data on the intrinsic subtype of the
TN wild-type tumors in this clinical trial have not been
reported yet and it might be interesting to analyze whether
the basal-like benefits the most. Supporting the hypothesis
that basal-like BRCA1 non-mutated breast cancers might
also benefit to some extent from DNA-damaging agents,
several studies have identified BRCA1 mutation-unrelated
mechanisms of platinum sensitivity in TN BRCA1 wild-
type breast cancer such as the p63/p73 network, telomeric
Breast Cancer Res Treat (2014) 147:185–191 189
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allelic imbalance, and homologous recombination defi-
ciency [27–29].
Conclusions
In this study, we compared DNA, RNA, and protein data
among basal-like tumors with and without BRCA1 muta-
tions and observed that minor molecular features exist. The
clinical relevance of these differences is unknown and
further validation in larger and prospective cohorts is
warranted. Biomarker analyses are needed to clarify if
BRCA1 status is an independent prognostic feature and/or a
predictive biomarker of benefit from DNA-damaging
agents beyond the basal-like phenotype.
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